WO2012172343A3 - Traitement de l'angiocholite sclérosante primitive - Google Patents

Traitement de l'angiocholite sclérosante primitive Download PDF

Info

Publication number
WO2012172343A3
WO2012172343A3 PCT/GB2012/051353 GB2012051353W WO2012172343A3 WO 2012172343 A3 WO2012172343 A3 WO 2012172343A3 GB 2012051353 W GB2012051353 W GB 2012051353W WO 2012172343 A3 WO2012172343 A3 WO 2012172343A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemokine receptor
sclerosing cholangitis
primary sclerosing
treating primary
ccr7
Prior art date
Application number
PCT/GB2012/051353
Other languages
English (en)
Other versions
WO2012172343A2 (fr
Inventor
Graham Cotton
Ola Winqvist
Original Assignee
Ith Immune Therapy Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ith Immune Therapy Holdings filed Critical Ith Immune Therapy Holdings
Publication of WO2012172343A2 publication Critical patent/WO2012172343A2/fr
Publication of WO2012172343A3 publication Critical patent/WO2012172343A3/fr
Priority to US14/105,628 priority Critical patent/US9726666B2/en
Priority to US15/629,705 priority patent/US10429385B2/en
Priority to US15/629,713 priority patent/US10408832B2/en
Priority to US15/629,700 priority patent/US10422800B2/en
Priority to US15/629,691 priority patent/US10451620B2/en
Priority to US15/629,697 priority patent/US10502736B2/en
Priority to US15/629,708 priority patent/US10401357B2/en
Priority to US16/537,224 priority patent/US20190361020A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis

Abstract

L'invention concerne une méthode de traitement de l'angiocholite sclérosante primitive consistant à appliquer du sang périphérique d'un patient ou sujet sur une colonne d'aphérèse chargée d'un support solide comprenant un ou plusieurs réactifs de liaison pouvant se lier spécifiquement à un récepteur de chimiokines, éventuellement le récepteur de chimiokines CCR9, CXCR4, CCR7 ou CCR5, immobilisé directement ou indirectement sur le support, éliminant ainsi au moins un récepteur de chimiokines, éventuellement des cellules exprimant CCR9, CXCR4, CCR7 et CCR5 à partir du sang périphérique du patient ou sujet. L'invention concerne en outre diverses méthodes thérapeutiques associées, ainsi que des réactifs de liaison utiles.
PCT/GB2012/051353 2011-06-13 2012-06-13 Traitement de l'angiocholite sclérosante primitive WO2012172343A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US14/105,628 US9726666B2 (en) 2011-06-13 2013-12-13 Diagnosing and treating inflammatory diseases
US15/629,705 US10429385B2 (en) 2011-06-13 2017-06-21 Treating conditions associated with sepsis
US15/629,713 US10408832B2 (en) 2011-06-13 2017-06-21 Treating mental disorders
US15/629,700 US10422800B2 (en) 2011-06-13 2017-06-21 Treating respiratory conditions
US15/629,691 US10451620B2 (en) 2011-06-13 2017-06-21 Treating conditions associated with metabolic syndrome
US15/629,697 US10502736B2 (en) 2011-06-13 2017-06-21 Treating multiple sclerosis
US15/629,708 US10401357B2 (en) 2011-06-13 2017-06-21 Treating cancer
US16/537,224 US20190361020A1 (en) 2011-06-13 2019-08-09 Treating respiratory conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496329P 2011-06-13 2011-06-13
US61/496,329 2011-06-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/051356 Continuation-In-Part WO2012172346A2 (fr) 2011-06-13 2012-06-13 Traitement de maladies respiratoires

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2012/051346 Continuation-In-Part WO2012172337A2 (fr) 2011-06-13 2012-06-13 Traitement de maladie cardiovasculaire
US14/105,628 Continuation-In-Part US9726666B2 (en) 2011-06-13 2013-12-13 Diagnosing and treating inflammatory diseases

Publications (2)

Publication Number Publication Date
WO2012172343A2 WO2012172343A2 (fr) 2012-12-20
WO2012172343A3 true WO2012172343A3 (fr) 2013-03-07

Family

ID=46317439

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/051353 WO2012172343A2 (fr) 2011-06-13 2012-06-13 Traitement de l'angiocholite sclérosante primitive

Country Status (1)

Country Link
WO (1) WO2012172343A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
GB202012451D0 (en) * 2020-08-11 2020-09-23 Univ Newcastle Biomarkers in primary biliary cholangitis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017979A1 (en) * 1999-03-11 2003-01-23 Matthias Mack Antibody and chemokine constructs and their use in the treatment of infections and immunological diseases
DE102005036505A1 (de) * 2004-07-30 2006-06-01 Adexter Gmbh Vorrichtung und Verfahren zum Isolieren von Zellen, Biopartikeln und/oder Molekülen aus Flüssigkeiten mit dem Ziel einer Anwendung zur Behandlung von Krankheiten des Menschen
WO2006126209A1 (fr) * 2005-05-26 2006-11-30 Rappaport Family Institute For Research In The Medical Sciences Polypeptides, compositions les comprenant et procedes les utilisant pour le traitement des conditions medicales associees a cxcr4
WO2007133147A1 (fr) * 2006-05-12 2007-11-22 Ibd Column Therapies International Ab Procédé et moyens pour traiter les maladies inflammatoires chroniques de l'intestin
WO2010029317A2 (fr) * 2008-09-10 2010-03-18 Ibd Column Therapies International Ab Traitement d’états inflammatoires

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2371849A1 (fr) 1999-02-22 2000-08-31 Millennium Pharmaceuticals, Inc. Complexes constitues d'un anticorps et de chimiokines biotinylees
SG193216A1 (en) 2008-08-18 2013-09-30 Amgen Fremont Inc Antibodies to ccr2

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017979A1 (en) * 1999-03-11 2003-01-23 Matthias Mack Antibody and chemokine constructs and their use in the treatment of infections and immunological diseases
DE102005036505A1 (de) * 2004-07-30 2006-06-01 Adexter Gmbh Vorrichtung und Verfahren zum Isolieren von Zellen, Biopartikeln und/oder Molekülen aus Flüssigkeiten mit dem Ziel einer Anwendung zur Behandlung von Krankheiten des Menschen
WO2006126209A1 (fr) * 2005-05-26 2006-11-30 Rappaport Family Institute For Research In The Medical Sciences Polypeptides, compositions les comprenant et procedes les utilisant pour le traitement des conditions medicales associees a cxcr4
WO2007133147A1 (fr) * 2006-05-12 2007-11-22 Ibd Column Therapies International Ab Procédé et moyens pour traiter les maladies inflammatoires chroniques de l'intestin
WO2010029317A2 (fr) * 2008-09-10 2010-03-18 Ibd Column Therapies International Ab Traitement d’états inflammatoires

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANDREA T BORCHERS ET AL: "Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis", SEMINARS IN IMMUNOPATHOLOGY, SPRINGER, BERLIN, DE, vol. 31, no. 3, 17 June 2009 (2009-06-17), pages 309 - 322, XP019758214, ISSN: 1863-2300, DOI: 10.1007/S00281-009-0167-2 *
B. EKSTEEN ET AL: "Hepatic Endothelial CCL25 Mediates the Recruitment of CCR9+ Gut-homing Lymphocytes to the Liver in Primary Sclerosing Cholangitis", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 200, no. 11, 6 December 2004 (2004-12-06), pages 1511 - 1517, XP055037419, ISSN: 0022-1007, DOI: 10.1084/jem.20041035 *
GRANT ALLISTER J ET AL: "Hepatic expression of secondary lymphoid chemokine (CCL21) promotes the development of portal-associated lymphoid tissue in chronic inflammatory liver disease", AMERICAN JOURNAL OF PATHOLOGY, vol. 160, no. 4, April 2002 (2002-04-01), pages 1445 - 1455, XP002683083, ISSN: 0002-9440 *
TERADA RYO ET AL: "Stromal cell-derived factor-1 from biliary epithelial cells recruits CXCR4-positive cells: implications for inflammatory liver diseases", LABORATORY INVESTIGATION, NATURE PUBLISHING GROUP, THE UNITED STATES AND CANADIAN ACADEMY OF PALHOLOGY, INC, vol. 83, no. 5, 1 May 2003 (2003-05-01), pages 665 - 672, XP008155843, ISSN: 0023-6837, DOI: DOI:10.1097/01.LAB.0000067498.89585.06 *

Also Published As

Publication number Publication date
WO2012172343A2 (fr) 2012-12-20

Similar Documents

Publication Publication Date Title
WO2012172341A3 (fr) Traitement du cancer
WO2010029317A3 (fr) Traitement d'états inflammatoires
WO2011008520A3 (fr) Procédés et dispositif de test d'analyte pour calculer une thérapie par insuline basale
EP2592140A4 (fr) Support pour immobilisation d'une protéine, protéine immobilisée et procédé de production associé
WO2016012285A3 (fr) Procédé
BR112013004750A2 (pt) derivados de quinolina e quinoxalina como inibidores da cinase
IL222252A0 (en) Methods, system and apparatus for the detection, diagnosis and treatment of biological rhythm disorders
WO2012149299A3 (fr) Procédés de traitement du cancer et de maladies inflammatoires au moyen de céréblon en tant que prédicteur
EP2244663A4 (fr) Dispositif, système et procédé d'élimination de caillots sanguins
BR112015012014A2 (pt) proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
HUP1200205A3 (en) Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
WO2013013025A3 (fr) Anticorps anti-cxcr4 et leurs procédés d'utilisation
WO2014093051A3 (fr) Cellules souches cardiaques et leurs procédés d'identification et d'utilisation
EP2700708A3 (fr) Amélioration de la capacité stimulatrice des lymphocytes T d'antigène humain présentant des cellules in vitro et in vivo et leur utilisation dans les vaccins
WO2011163566A3 (fr) Méthodes de traitement de patients souffrant de maladies se rapportant au système immunitaire
WO2009040413A3 (fr) Procédé ex vivo, rapide et efficace pour obtenir des cellules présentant un antigène activé, qui sont utiles pour des thérapies contre le cancer et des maladies liées au système immunitaire
WO2010009129A3 (fr) Méthodes de traitement de maladies auto-immunes utilisant des anticorps cd4
WO2012172343A3 (fr) Traitement de l'angiocholite sclérosante primitive
WO2012066495A3 (fr) Thérapie à base de cellules t pour les maladies neurodégénératives
WO2008157222A3 (fr) Dispositif et procédés pour introduire un cathéter dans un disque intervertébral
WO2014049438A3 (fr) Procédé de détermination non invasive de la concentration de glucose sanguin et dispositif pour sa mise en œuvre
WO2012172337A3 (fr) Traitement de maladie cardiovasculaire
WO2014008118A3 (fr) Méthode de traitement simultané de la douleur et de la dépression
WO2012172344A3 (fr) Traitement d'états associés à la sepsie
WO2012172340A3 (fr) Traitement de troubles mentaux

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12727918

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12727918

Country of ref document: EP

Kind code of ref document: A2